UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.
AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug.